GlassScriptPhysician profile
Ashley Adams
NPI 1982258190
$3,553.37
in general payments reported to CMS, 2019-2025
25 companies · $399 in 2025
The $399 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,542 · 2022: $253 · 2023: $624 · 2024: $737 · 2025: $399.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,759.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,758.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Livanova USA, INC. | $1,541.68 | 2021 | |
| Abbvie INC. | $415.54 | 2023-2025 | Ubrelvy, Botox, Qulipta |
| Ucb, INC. | $174.33 | 2023-2025 | Fintepla, Nayzilam |
| Argenx US, INC. | $159.56 | 2022-2025 | Vyvgart Hytrulo, Vyvgart |
| Sk Life Science, INC. | $154.61 | 2023-2024 | Xcopri |
| Ironshore Pharmaceuticals INC. | $116.47 | 2022 | |
| Pfizer INC. | $116.09 | 2023-2025 | |
| Lilly USA, LLC | $94.39 | 2022-2025 | Amyvid, Kisunla, Emgality |
| Alexion Pharmaceuticals, INC. | $82.38 | 2023-2024 | Ultomiris, Soliris |
| Otsuka America Pharmaceutical, INC. | $69.32 | 2024-2025 | Rexulti |
| Eisai INC. | $66.49 | 2024-2025 | |
| Glaxosmithkline, LLC. | $59.41 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Novartis Pharmaceuticals Corporation | $57.18 | 2023-2025 | |
| Genentech USA, INC. | $52.09 | 2023-2024 | Ocrevus, Enspryng |
| Ani Pharmaceuticals, INC. | $51.88 | 2023-2024 | Purified Cortrophin Gel |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merz Pharmaceuticals, LLC | $49.55 | 2024-2025 | Xeomin, Inbrija |
| Medtronic, INC. | $46.81 | 2024 | Percept PC Brainsense |
| Csl Behring | $44.22 | 2024 | Hizentra |
| Janssen Pharmaceuticals, INC | $39.66 | 2022 | |
| Tg Therapeutics, INC. | $39.03 | 2025 | |
| Amgen INC. | $38.09 | 2023-2024 | Otezla, Repatha |
| Boston Scientific Corporation | $31.29 | 2023 | Vercise |
| Amneal Pharmaceuticals LLC | $20.90 | 2024 | Rytary |
| Kyowa Kirin, INC. | $16.46 | 2024 | Nourianz |
| Biohaven Pharmaceutical Holding Company LTD. | $15.94 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Adams listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.